Beyond DNA repair: the novel immunological potential of PARP inhibitors

Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, confer sensitivity to poly-(ADP-ribose) polymerase inhibitors (PARPi). Our work...

Descripción completa

Detalles Bibliográficos
Autores principales: Chabanon, Roman M., Soria, Jean-Charles, Lord, Christopher J., Postel-Vinay, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512907/
https://www.ncbi.nlm.nih.gov/pubmed/31131303
http://dx.doi.org/10.1080/23723556.2019.1585170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512907/
https://www.ncbi.nlm.nih.gov/pubmed/31131303
http://dx.doi.org/10.1080/23723556.2019.1585170

Ejemplares similares